Epidemiologic evaluation of inhaled nitric oxide use among neonates with gestational age less than 35 weeks

Epidemiologic evaluation of inhaled nitric oxide use among neonates with gestational age less than 35 weeks

Background and Objectives The use of inhaled nitric oxide (iNO) in +late preterm and term infants with pulmonary hypertension is Food and Drug Administration (FDA) approved and has improved outcomes and survival. iNO use is not FDA approved for preterm infants and previous studies show no mortality...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric pulmonology 2022-02, Vol.57 (2), p.427-434
Hauptverfasser: Peluso, Allison M., Othman, Hasan F., Karnati, Sreenivas, Sammour, Ibrahim, Aly, Hany Z.
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Inhalation
Cross-Sectional Studies
FDA approval
Gestational Age
health services
Humans
hypoxic respiratory failure
Infant
Infant, Newborn
Infant, Premature
Mortality
Nitric oxide
Nitric Oxide - therapeutic use
prematurity
pulmonary hypertension
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and Objectives The use of inhaled nitric oxide (iNO) in +late preterm and term infants with pulmonary hypertension is Food and Drug Administration (FDA) approved and has improved outcomes and survival. iNO use is not FDA approved for preterm infants and previous studies show no mortality benefit. The objectives were 1) to determine the usage of iNO among preterm neonates
ISSN:8755-6863
1099-0496
DOI:10.1002/ppul.25775